FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype

FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

Want the FDA to Make Peptides Safer? 83% of You Said Yes

A new survey suggests Americans want a clearer, medically supervised way to access popular peptides.  Among 2,491 peptide-aware U.S. adults surveyed by Hone Health in May 2026, 83% support allowing licensed compounding pharmacies to produce popular peptides with a physician’s prescription.  The finding comes days before an FDA advisory committee meets to consider whether seven widely used peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP…

APhA urges FDA to put patient safety first in review of peptide substances

WASHINGTON – As the market for unregulated peptide products continues to grow, the American Pharmacists Association (APhA) is urging FDA and the Pharmacy Compounding Advisory Committee (PCAC) to prioritize patient safety, scientific evidence, and regulatory oversight as they evaluate several peptide substances nominated for inclusion on the Section 503A Bulks List.In comments submitted to FDA, APhA highlighted the emergence of black and gray mar…